ATE519480T1 - Konzentrierte flüssige schilddrüsenhormonzusammensetzung - Google Patents
Konzentrierte flüssige schilddrüsenhormonzusammensetzungInfo
- Publication number
- ATE519480T1 ATE519480T1 AT07703665T AT07703665T ATE519480T1 AT E519480 T1 ATE519480 T1 AT E519480T1 AT 07703665 T AT07703665 T AT 07703665T AT 07703665 T AT07703665 T AT 07703665T AT E519480 T1 ATE519480 T1 AT E519480T1
- Authority
- AT
- Austria
- Prior art keywords
- thyroid hormone
- concentrated liquid
- composition
- hormone composition
- treat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title abstract 3
- 239000005495 thyroid hormone Substances 0.000 title abstract 3
- 229940036555 thyroid hormone Drugs 0.000 title abstract 3
- 239000007788 liquid Substances 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- -1 cyclodextrin compound Chemical class 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75677706P | 2006-01-06 | 2006-01-06 | |
| EP06100133 | 2006-01-06 | ||
| PCT/EP2007/050107 WO2007077252A1 (en) | 2006-01-06 | 2007-01-05 | Concentrated liquid thyroid hormone composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE519480T1 true ATE519480T1 (de) | 2011-08-15 |
Family
ID=37833322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07703665T ATE519480T1 (de) | 2006-01-06 | 2007-01-05 | Konzentrierte flüssige schilddrüsenhormonzusammensetzung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8318712B2 (de) |
| EP (1) | EP1973524B1 (de) |
| JP (1) | JP5173832B2 (de) |
| KR (1) | KR20080083685A (de) |
| AT (1) | ATE519480T1 (de) |
| CA (1) | CA2634993A1 (de) |
| WO (1) | WO2007077252A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1395454B1 (it) * | 2009-03-24 | 2012-09-21 | Altergon Sa | Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale |
| PL2683361T5 (pl) * | 2011-03-10 | 2024-09-09 | Helm Swiss Gmbh | Sposób wytwarzania roztworu lewotyroksyny |
| US10328152B2 (en) | 2011-06-16 | 2019-06-25 | Nayan Patel | Method for stabilization and delivery of therapeutic molecules |
| EP2750664A1 (de) | 2011-08-30 | 2014-07-09 | Fresenius Kabi USA, LLC | Levothyroxinformulierungen |
| DE102013017917A1 (de) * | 2013-10-26 | 2015-04-30 | Michael Raschke | L-Thyrogal |
| WO2017002751A1 (ja) * | 2015-06-29 | 2017-01-05 | 富士レビオ株式会社 | 甲状腺ホルモン類標準液 |
| WO2017013591A1 (en) | 2015-07-22 | 2017-01-26 | Leiutis Pharmaceuticals Pvt Ltd | Stabilized liquid formulation of levothyroxine |
| US11364196B2 (en) * | 2015-11-04 | 2022-06-21 | Leiutis Pharmaceuticals Pvt. Ltd. | Levothyroxine formulations for oral use |
| NL2017110B1 (en) * | 2016-07-05 | 2018-01-12 | Emp Levo Gmbh | Methods for the preparation of a levothyroxine solution |
| EP3311844A1 (de) | 2016-10-18 | 2018-04-25 | Altergon S.A. | Hochstabile verpackte lösungen von t4-schilddrüsenhormon |
| US9782376B1 (en) * | 2016-12-01 | 2017-10-10 | Fresenius Kabi Usa Llc | Levothyroxine liquid formulations |
| WO2019023791A1 (en) * | 2017-07-31 | 2019-02-07 | Apollo Pharmaceuticals Inc. | LEVOTHYROXIN FORMULATIONS |
| US11241382B2 (en) | 2019-03-01 | 2022-02-08 | Altergon Sa | Administration regimen of compositions of T4 thyroid hormone with high oral absorption |
| US20230338320A1 (en) | 2019-11-22 | 2023-10-26 | Wockhardt Limited | Oral film composition comprising levothyroxine |
| EP4704805A2 (de) * | 2023-05-02 | 2026-03-11 | Labomed Pharmaceutical Company S.A. | Orale lösung mit liothyronin-natrium |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
| GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
| GB9401891D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
| US5955105A (en) * | 1995-11-14 | 1999-09-21 | Knoll Pharmaceutical Company | Stabilized thyroid hormone preparations and methods of making same |
| HUT75956A (en) * | 1995-11-29 | 1997-05-28 | Cyclolab | Pharmaceutical composition containing thyroxine |
| RU2359698C2 (ru) * | 2002-09-13 | 2009-06-27 | Сайдекс, Инк. | Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина |
| GB0316206D0 (en) * | 2003-07-10 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulation |
-
2007
- 2007-01-05 AT AT07703665T patent/ATE519480T1/de not_active IP Right Cessation
- 2007-01-05 JP JP2008549014A patent/JP5173832B2/ja active Active
- 2007-01-05 EP EP07703665A patent/EP1973524B1/de active Active
- 2007-01-05 US US12/160,292 patent/US8318712B2/en active Active
- 2007-01-05 CA CA002634993A patent/CA2634993A1/en not_active Abandoned
- 2007-01-05 WO PCT/EP2007/050107 patent/WO2007077252A1/en not_active Ceased
- 2007-01-05 KR KR1020087018396A patent/KR20080083685A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009522335A (ja) | 2009-06-11 |
| EP1973524B1 (de) | 2011-08-10 |
| US8318712B2 (en) | 2012-11-27 |
| US20090270507A1 (en) | 2009-10-29 |
| EP1973524A1 (de) | 2008-10-01 |
| KR20080083685A (ko) | 2008-09-18 |
| WO2007077252A1 (en) | 2007-07-12 |
| CA2634993A1 (en) | 2007-07-12 |
| JP5173832B2 (ja) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE519480T1 (de) | Konzentrierte flüssige schilddrüsenhormonzusammensetzung | |
| HN2006000971A (es) | Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1 | |
| EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
| GT200800151A (es) | Inhibidores de 11-beta-hsd1 | |
| MX2009006481A (es) | Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona. | |
| EP2279244A4 (de) | Verfahren und zusammensetzungen zur oralen verabreichung von proteinen | |
| EA200970175A1 (ru) | Способы и композиции для ингибирования ангиогенеза | |
| MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
| MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
| EP2506717A4 (de) | Verfahren zur verwendung von dopamin-wiederaufnahmehemmern und ihren analogen zur behandlung von diabetessymptomen und zur verzögerung oder verhinderung von mit diabetes assoziierten erkrankungen | |
| BRPI0712631B8 (pt) | compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações | |
| EA200970580A1 (ru) | Таннат разагилина | |
| MX356584B (es) | Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica. | |
| MA32981B1 (fr) | Regime posologique pour un agoniste du recepteur s1p | |
| DE602007012559D1 (de) | H die schleimhaut | |
| ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
| WO2007098099A3 (en) | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | |
| IL193479A0 (en) | Modulators of muscarinic receptors | |
| WO2009124294A3 (en) | Pharmaceutical compositions for binding sphingosine-1-phosphate | |
| EA201000391A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
| EA200970597A1 (ru) | Новые бис(диалкиламиды), способ получения и применения | |
| DK1931335T3 (da) | Hexahydro-cyclooctyl-pyrazol-cannabinoid-modulatorer | |
| EA201000392A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
| DK2041181T3 (da) | Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi | |
| TW200744577A (en) | Method for treating osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |